Make Informed Investment Decisions with Affordable Access to Experts

This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

A Second Opinion: Preparing for Eptinezumab's data in Chronic Migraine after study changes and additional data from Erenumab

Ticker(s): ALDR, AMGN, TEVA, NVS

Who's the expert?

A headache specialist who is familiar with the CGRP developmental landscape and data, but not working with ALDR specifically. An independent and informed voice will be essential.

Interview Questions
Q1.

Please describe your clinical practice in terms of Chronic and Frequent Episodic Migraine patients.

Added By: joe_mccann
Q2.

Do you have any history or relationship with the development of CGRPs as a class? If so which?

Added By: joe_mccann
Q3.

How concerned are you about the change from 12 weeks to 24 weeks for the first look at PROMISE 1 data?

Added By: joe_mccann
Q4.

Based on clinicaltrial.gov records it looks like enrollment has increased from 600 to 900 patients. How concerning is this to you? https://twitter.com/WilliamGerber1/status/852209231679893504/photo/1

Added By: joe_mccann
Q5.

How does the profile thus far of Eptinezumab look compared to Erenumab's STRIVE results?

Added By: joe_mccann
Q6.

What percent of the migraine population will use and IV vs. subcutaneous administration? Would that differ between frequent episodic vs. chronic migraine? What about IV administration would make it preferred vs. subcutaneous administration?  

Added By: user9bc04687
Q7.

How does the recently reported STRIVE and ARISE Ph3 data from Amgen shape your thoughts on which CGRP Ab therapy is best? How does eptinezumab stack up against the competition in both frequent episodic and chronic migraine? 

Added By: user9bc04687
Q8.

Do oral CGRP inhibitors currently in development have a realistic chance to succeed in the market based on what you know about safety and efficacy?

Added By: william gerber
Q9.

Any update on positive or negative safety/efficacy differences between receptor (Amgen) vs ligand (Alder, Teva, Lilly) CGRP inhibitors?

Added By: william gerber
Q10.

Any update on potential market size for CGRP inhibitors given Amgen/Novartis ARISE study only 1.1 day/month reduction vs placebo (2.9 vs 1.8 placebo) in episodic migraine and the STRIVE trial which showed 1.4 to 1.9 day reduction of episodic migraine day reduction vs placebo (3.2 to 3.7 vs 1.8 day). Are these reductions vs placebo going to create large demand?

Added By: william gerber
Q11.

What do you feel is the most important trial endpoint for CGRP inhibitors?  Average headache reduction days, percent 100% responders, 75% responders, 50% responders? Other?

Added By: william gerber

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.